FluoGuide A/S (STO:FLUO)
Sweden
· Delayed Price · Currency is SEK 35.80
-0.10 (-0.28%)
At close: Feb 27, 2026
FluoGuide Company Description
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark.
The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies.
It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer.
The company was incorporated in 2018 and is based in Copenhagen, Denmark.
FluoGuide A/S
| Country | Denmark |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Morten Albrechtsen |
Contact Details
Address: Titanhus, Titangade 9-13 Copenhagen, 2200 Denmark | |
| Phone | 45 31 22 66 60 |
| Website | fluoguide.com |
Stock Details
| Ticker Symbol | FLUO |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0061123312 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Morten Albrechtsen B.B.A., M.D. | Chief Executive Officer |
| Ole Larsen Cand. merc., M.Sc. | Chief Financial Officer |
| Donna Haire | Chief Operating Officer |
| Prof. Andreas Kjaer M.D., M.Sc., Ph.D. | CSO, Head of Scientific Advisory Board and Director |
| Dr. Grethe Nørskov Rasmussen M.Sc., Ph.D. | Chief Development Officer |
| Dr. Jens Ellrich M.D., Ph.D. | Chief Medical Officer |
| Dorthe Gronnegaard Mejer | Vice President of Clinical Development |